Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. It has been postulated that the accumulation of advanced glycation end products (AGEs) in the kidney is important in the pathogenesis of diabetic ncphropathy. Previously, aminoguanidine has been shown to inhibit the accumulation of renal AGEs and to retard the development of experimental diabetic nephropathy. The present study serially assessed the accumulation of AGEs in the aorta and kidney, as well as renal functional and structural parameters over 32 weeks of experimental diabetes in the absence and presence of aminoguanidine. In addition, it was determined if aminoguanidine was more effective if administered earlier or later in the evolution of diabetic nephropathy by treating diabetic rats with aminoguanidine in the first or second half of the 32-week study period. In the serial studies, glomerular and renal tubular fluorescence increased over the 32 week period and this increase was attenuated by aminoguanidine treatment. Concomitant with the effects of aminoguanidine on fluorescence, there was a retardation in the rise in urinary albumin excretion and prevention of mesangial expansion. Early or late administration of aminoguanidine in diabetic rats reduced tissue fluorescence in glomeruli and renal tubules. At 32 weeks, renal AGEs were increased in diabetic rats as assessed by tissue fluorescence. Using a specific RIA, renal AGEs were increased in diabetic rats and decreased by aminoguanidine treatment, administered over the entire 32 weeks or in the first or latter half of the 32-week study period. Aminoguanidine therapy for the entire 32-week study period retarded the rise in albuminuria in the diabetic rats and was more effective than 16 weeks of treatment either in the first or second half of the study. Early and late aminoguanidine administration were similar in their capacity to retard the development of albuminuria in diabetic rats. Similiar effects were observed on mesangial expansion. The increased glomerular basement thickness in diabetic rats was not affected by aminoguanidine, irrespective of duration or timing of therapy. This study confirms that in viva generation of AGEs in the kidney is time dependent and closely linked to the development of experimental diabetic nephropathy. The renoprotective effects of aminoguanidine in diabetes appear to be related to the duration but not to the timing of treatment.
Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. It has been postulated that the accumulation of advanced glycation end products (AGEs) in the kidney is important in the pathogenesis of diabetic ncphropathy. Previously, aminoguanidine has been shown to inhibit the accumulation of renal AGEs and to retard the development of experimental diabetic nephropathy. The present study serially assessed the accumulation of AGEs in the aorta and kidney, as well as renal functional and structural parameters over 32 weeks of experimental diabetes in the absence and presence of aminoguanidine. In addition, it was determined if aminoguanidine was more effective if administered earlier or later in the evolution of diabetic nephropathy by treating diabetic rats with aminoguanidine in the first or second half of the 32-week study period. In the serial studies, glomerular and renal tubular fluorescence increased over the 32 week period and this increase was attenuated by aminoguanidine treatment. Concomitant with the effects of aminoguanidine on fluorescence, there was a retardation in the rise in urinary albumin excretion and prevention of mesangial expansion. Early or late administration of aminoguanidine in diabetic rats reduced tissue fluorescence in glomeruli and renal tubules. At 32 weeks, renal AGEs were increased in diabetic rats as assessed by tissue fluorescence. Using a specific RIA, renal AGEs were increased in diabetic rats and decreased by aminoguanidine treatment, administered over the entire 32 weeks or in the first or latter half of the 32-week study period. Aminoguanidine therapy for the entire 32-week study period retarded the rise in albuminuria in the diabetic rats and was more effective than 16 weeks of treatment either in the first or second half of the study. Early and late aminoguanidine administration were similar in their capacity to retard the development of albuminuria in diabetic rats. Similiar effects were observed on mesangial expansion. The increased glomerular basement thickness in diabetic rats was not affected by aminoguanidine, irrespective of duration or timing of therapy. This study confirms that in viva generation of AGEs in the kidney is time dependent and closely linked to the development of experimental diabetic nephropathy. The renoprotec-results from a complex reaction in which glucose together with proteins partake in a process known as the Maillard reaction [2] .
It has been postulated that the link between the biochemical process of advanced glycation and the development of diabetic complications relates to the presence of AGE products in diabetic tissues [5] as has been observed in studies in both humans [61 and rodents [7, 8] . Our group has previously reported increased levels of AGEs, as defined by tissue fluorescence, in the rat kidney after 32 weeks of streptozocin diabetes [7] . This was associated with alterations in renal functional as well as structural parameters such as albuminuria and mesangial expansion. Aminoguanidine, a hydrazine-like compound (AG), attenuated the rise in albuminuria and prevented mesangial expansion in these diabetic rats. Aminoguanidine treatment also prevented diabetes-related increases in collagen-related fluorescence in the renal glomeruli and tubules. Ellis and Good have reported in a small number of animals that AG prevented glomerular basement membrane thickening [9] , but in our previous study no such effect of AG was observed [7] . Therefore, the effects of AG on the kidney in experimental diabetes remain controversial.
The hypothesis that the accumulation of AGEs in diabetic tissues is associated with complications has previously relied on cross sectional data from diabetic animals [7] and humans [2] .
This study has explored the relationship of accumulation of renal AGEs, measured by radioimmunoassay as well as by tissue fluorescence, to the development of experimental diabetic nephropathy. In addition, the time course of the effects of aminoguanidine in ameliorating diabetes-related renal injury and inhibiting AGE formation has been assessed. To explore if aminoguanidine is able to reverse, as well as prevent the development of diabetic nephropathy, aminoguanidine was administered for the whole duration or for the first or second half of the 32-week study period.
Methods
Male Sprague-Dawley rats, six weeks of age, weighing between 200 and 250 g were randomized to control or diabetic groups.
Diabetes was induced by intravenous injection of streptozocin (60 mg/kg body wt in citrate buffer, pH 4.5) after an overnight fast and all animals with plasma glucose levels > 20 m after one week were included in the study. The control group was sham injected with citrate buffer alone. In the initial study (study protocol I), diabetic rats were randomized to receive no treatment or aminoguanidine (AG) hydrogen carbonate 1 g/liter in drinking water (Fluka Chemica, Buchs, Switzerland). Rats were sacrificed at weeks 0, 8, 16 and 32 weeks. A separate group of control rats received aminoguanidine (2 glliter in drinking water) and this group was sacrificed at week 32 only.
Based on the findings of this study that showed a marked increase in fluorescence and albuminuria in diabetic rats over weeks 16 to 32 (see below), a second study was performed. In the latter study (study protocol II), diabetic animals were randomized into four groups. One group received no therapy, one group received AG I g/liter in drinking water for the whole 32 week period, another group was administered AG for the first 16 weeks of the study only (early intervention), and the final group received AG for only the last 16 weeks (late intervention). Control rats received citrate buffer alone.
All rats were given free access to food throughout the study (GR2 rat cubes; Clark King and Co., Melbourne, Australia).
Diabetic rats received 2 units of ultralente insulin (Ultratard HM; Novo Industries, Bagsvaerd, Denmark) every second day to maintain body weight and improve survival over the 32-week study period. Rats were caged in groups of three. At eight weekly intervals, rats were weighed and placed in metabolic cages (Iffa Credo, L'Abresele, France) for collection of 24-hour urine samples that were stored at -20°C and later assayed for albumin concentration. Blood was collected from the tail vein at eight weekly intervals for the measurement of plasma glucose and glycosylated hemoglobin. Plasma glucose was measured by a glucose oxidase technique [10] and glycosylated hemoglobin was measured by a high performance liquid chromatography technique (Bio-rad, Richmond, CA, USA). Urinary albumin concentration was measured by radioimmunoassay [11] . The interassay coefficient of variation was 7% (N = 50) at a concentration of 180 ng/ml and the detection limit of the assay was 31.2 ng/ml.
In a subgroup of animals, blood pressure was measured by rat tail plethysmography [121 and glomerular filtration rate (GFR) was measured by a single injection isotope technique [131 at 32 weeks.
Rats were anesthetized with pentobarbital sodium (Nembutal, Bomac, Asquith, Australia) and the left kidney was excised followed by the removal of the lower abdominal aorta and right and left common iliac arteries. These tissues were immediately snap frozen in liquid N2 and stored at -80°C. The preparation of tissues for measurement of collagen-related fluorescence is outlined below and is based on previously published methods [71. In brief, the left kidney was finely minced and was processed to isolate glomeruli and tubules. Glomeruli and tubules were separated by differential sieving with stainless steel mesh with pore sizes of 250 to 75 jm yielding 15 to 20,000 glomeruli/kidney. The purity of the glomerular preparations was greater than 95%. The aorta was homogenised by a Polytron homgenizer (Ultra-Tumax, Janke and Kunel, Staufen, Germany). The isolated renal glomeruli and tubules as well as the homogenized aorta were suspended in phosphate buffered saline (pH 7.4) followed by centrifugation at 15,000 rpm for 30 minutes at 4°C. Lipid extraction of the pellet was performed by addition of 5 ml of chloroform/methanol (2:1 vol/vol) followed by gentle shaking and standing overnight at 4°C.
The upper layer was removed and the pellet was washed three times each with methanol and distilled water. The pellet was then resuspended in 0.5 M acetic acid and I mg/mI pepsin, incubated for 18 hours at 4°C to remove non-collagenous proteins, and washed twice with 0.1 M calcium chloride, 0.02 M Tris-HCI (pH 7.5) and 0.05% toluene. No specific fluorescence could be detected in the supernatants at this stage of the extraction procedure. The pellet was then digested with type IV collagenase 0.1 mg/mi, (Sigma, St. Louis, MO, USA) and proteinase K, 0.1 mg/mI, (Sigma) by gentle shaking at 37°C for 72 hours and centrifuged at 15,000 rpm for 30 minutes at 4°C. The resulting supernatant was used to measure collagen-related fluorescence with excitation/ emission at 370/440 nm. The fluorescence of an enzyme blank (type IV collagenase and proteinase K) was subtracted from the tissue fluorescence measurements. A colorimetric technique was used for the measurement of protein content [14] of the supernatants from each of the various tissue sampies. Pilot studies [15] by our group have indicated that collagen-related fluorescence is unaffected in control rats receiving aminoguanidine.
A specific radioimmunoassay was developed in our laboratory for the measurement of advanced glycated end products. The antibody used in this assay was directed against advanced glycated RNase [161. AGE-RNase was iodinated using lactoperoxidase [17] . The AGE-RNase standards (generated as a result of 6 months incubation of RNase with 0.5 M glucose in 0.2 M phosphate buffer at 37°C) or collagenase extracted renal homogenates, prepared as described above, were incubated with AGE-RNase antibody and tracer for five hours at room temperature. Sheep anti-rabbit IgG was then added and incubated overnight at room temperature. Precipitation of proteins was carried out by addition of 8% polyethylene glycol. The minimum concentration detectable was 250 mg/ml and the CV of this assay was 11.9%, N = 4, at a concentration of 2000 ng AGE-RNase/ml. Radioactivity was measured using a gamma counter (Canberra Packard Instruments, St. Louis, MO, USA) and the amount of AGEs present was expressed as ng AGE-RNase/j.tmol hydroxyproline. Hydroxyproline was measured in tissue samples by a colorimetric technique [18] . The right kidney was perfused in vivo at systolic blood pressure by an intra-aortic cannula initially with saline, followed by 2.5% glutaraldehyde [19] . A portion of the fixed kidney was prepared for electron microscopy. Briefly, 1 mm3 cubes were obtained from deep areas of the renal cortex at least 4 mm from the external surface and these sections were left for an additional 12 hours in the glutaraldehyde fixative followed by 0.1 M phosphate buffer for 72 hours. The blocks were then rehydrated in acetone followed by infiltration with araldite-Epon resin. The blocks were polymerised in an oven at 60°C for three days. Thick sections (1 rm) were cut and placed on a slide and stained with methylene blue. Glomeruli were located with light microscopy, the blocks trimmed and 50 nm sections cut. Sections were picked up on a Formvar-coated single-hole grid (SPI, Westchester, PA, USA) saturated with uranyl nitrate and Reynold's lead citrate and viewed using a Jeol 1200EX transmission electron microscope (Jeol, Tokyo, Japan). Twenty evenly spaced electron photomicrographs at a final magnification of approximately X 18,000 were taken with a 5 X 4 grids from 2 glomeruli per rat. GBM thickness was measured by the orthogonal intercept method [201. At least 50 orthogonal intercept measurements were performed on each glomerulus. As previously described [21, 22] , mesangium was defined as the areas delineated towards the capillary basement membrane where the endothelial and epithelial sides of the basement membrane are running parallel. Where the parallelism was lost and the distance between endothelial and epithelial cells widened it was viewed that this was the site where the mesangial region had ended. Fractional mesangial volume was determined after mesangium had been identified in the electron micrographs by an independent observer. A point-counting method was used with a 180-point grid to determine the percentage of glomerular tuft occupied by the mesangium [22] . Two glomeruli were studied per rat with a mean CV between glomeruli of 14%.
Statistics
Logarithmic transformation of urinaly albumin data were performed to yield a normal distribution for this parameter. The specific contributions of diabetes, time and aminoguanidine therapy and possible interactions were assessed by analysis of variance. Only data from animals which survived until time of sacrifice were analyzed. Up to 30% of diabetic rats died before week 32, the majority of deaths occuring in the first four weeks. There was no difference in survival between untreated and aminoguanidine treated diabetic rats. Comparison of normally distributed variables among the different groups during the study was performed by analysis of variance with or without repeated measures using the Statview SE Program (Brainpower, Calabasas, CA, USA) on a Macintosh LC475 personal computer (Apple, Cupertino CA, USA). Comparisons among groups at specific time points were performed by Fisher's least significant difference method. A P value of less than 0.05 was viewed as statistically significant. All data are shown as mean SE unless otherwise specified.
Results
Study protocol I Serial body wt and glycemic control are shown in Table 1 . Diabetic rats had significantly lower body wts than control rats throughout the duration of the study. Aminoguanidine therapy did not influence body wt in diabetic rats over the 32 weeks of treatment. Diabetes was associated with significantly elevated glucose and HbAlc levels throughout the study when compared to control rats. Aminoguanidine therapy did not influence glycemic control in diabetic rats at any time point. Control rats treated with aminoguanidine had similar plasma glucose levels (7.8 0.4, N = 11) and HbAlc (2.1 0.2%, N = 11) to untreated control rats. In the groups studied for 32 weeks, there was no effect of AG on systolic blood pressure (Control, 121 8; Diabetes, 142 12; Diabetes+AG, 131 4 mm Hg).
Renal fluorescence (glomeruli and tubules) for the various groups is shown in Figure 1 . In diabetic rats there was an increase in glomerular and tubular fluorescence over time, leading to significantly increased levels at 8, 16, and 32 weeks in diabetic compared to control rats. Aminoguanidine attenuated the rise in glomerular as well as tubular fluorescence in the diabetic rats so Serial functional and structural data are shown in Table 2 .
Albuminuria levels increased in control and diabetic rats over the study period. Diabetes was associated with significantly increased albuminuria over the 32-week study period when compared to control rats. Treatment of diabetic rats with aminoguanidine significantly retarded the rise in albuminuria at 16 and 32 weeks.
In control rats treated with aminoguanidine, there was no effect on albuminuria (week 32, control + aminoguanidine, 1.0 X/± 0.1 mg/24hr,N= 11).
Fractional mesangial volume was not increased in control rats over time. However, there was a significant increase in mesangial expansion in diabetic compared to control rats at weeks 8 and 32. There was a trend towards an increase at week 16 but this did not reach statistical significance (P < 0.10). The increase in mesangial expansion was significantly attenuated by aminoguanidine therapy at weeks 8 and 32. No effect of aminoguanidine on this parameter was observed in control rats (week 32, 13.6 0.8%). GBM thickness increased over the 32 weeks study period in both control and diabetic rats. Diabetes was associated with a significant increase in GBM thickness at week 32. Aminoguanidine therapy did not reduce glomerular basement membrane thickness in diabetic rats at week 32. No effect of aminoguanidine was observed on GBM thickness in control rats at week 32 (168 5 nm).
Study protocol II
Glycemic controls and body weights are shown in Table 3 .
There was a significant increase in body weight over time in both control and diabetic rats. Administration of aminoguanidine throughout the study period, did not affect body weight. Early as well as late intervention with aminoguanidine in diabetic rats was associated with a slight decrease in body weight at 32 weeks when compared to untreated animals. However, this retarded weight gain was not reflected by differences in glycemic control. Diabetes was associated with a significant elevation in plasma glucose levels as well as glycosylated hemoglobin. Aminoguanidine therapy whether it was administered throughout, early or late in the experimental procedure did not influence plasma glucose or HbAlc.
There was a significant increase in aortic fluorescence corrected for protein content in diabetic rats (control 1.58 0.49, diabetic 3.68 0.22, arbitrary units/mg protein, P < 0.01). Chronic therapy with aminoguanidine prevented the increase in aortic fluorescence resulting in levels from diabetic rats being similar to those observed in control rats (diabetic + aminoguanidine 2.29 0.19, arbitrary units/mg protein, P < 0.01 vs. diabetic). Early (0 to 16 weeks) as well as late (16 to 32 weeks) administration of aminoguanidine prevented the increase in aortic fluorescence to a similar degree (early intervention 1.64 0.42; late intervention 1.07 0.31, arbitrary units/mg protein, P < 0.01 vs. diabetic). In isolated renal tubules and glomeruli, diabetes was associated with a significant increase in fluorescence and this was prevented by administration of aminoguanidine to a similar degree whether it was given throughout, early or late in the experimental protocol (Fig. 2) .
The amounts of advanced glycation end products, as assessed by RIA, in renal glomeruli and tubules at 32 weeks are shown in Figure 3 . There was a significant increase in AGEs in homogenates from glomeruli and tubules of the diabetic rats when compared to control rats at week 32. Treatment with aminoguanidine, administered either throughout the 32 weeks period or for the first or latter 16 weeks of the entire study period, reduced AGEs levels in renal homogenates at week 32. There was a significant increase in albuminuria over the 32 week study in diabetic rats as compared to control rats (Fig. 4) . The rise in albuminuria in diabetic rats was markedly attenuated by aminoguanidine therapy with levels in this group being lower than in the untreated diabetic rats at 8, 24 and 32 weeks, respectively. At week 16 there was a trend towards less albuminuria in AG treated rats but this did not reach statistical significance. Urinary albumin excretion in the early and late intervention groups at 24 and 32 weeks was intermediate between the results of rats treated with AG throughout and untreated diabetic rats. At week 16, the early but not the late intervention group had lower levels of albuminuria than the untreated diabetic rats. Diabetic rats had significantly increased fractional mesangial volume at 32 weeks as compared to control rats. Chronic administration of aminoguanidine significantly inhibited mesangial expansion at 32 weeks as compared to control rats. The effects of early or late intervention with aminoguanidine on mesangial expansion were intermediate between untreated diabetic rats and chronically aminoguanidine treated rats. Diabetes was associated with significantly increased GBM thickness at 32 weeks when compared to control rats. Administration of aminoguanidine whether it was throughout, early or late did not significantly affect GBM thickness in diabetic rats at 32 weeks.
Discussion
In the present study we have confirmed that in vivo generation of AGEs, as measured by tissue fluorescence, is time dependent. Similar findings of increased AGEs in diabetes have been previously described using various techniques including tissue fluorescence [7, 8, 23, 24] , immunochemical methods [4, 6, 16] and radioreceptor assays [25] . Concomitant with the increase in tissue advanced glycation end products there was evidence of diabetic nephropathy, as assessed by both structural and functional parameters. Administration of aminoguanidine throughout the entire study period prevented accumulation of kidney AGEs. In addition, we have confirmed our previous finding that aminoguanidine ameliorates the development of diabetic nephropathy, as defined by attenuation of the rise in albuminuria and prevention of mesangial expansion [7] . As in our previous study, the increase in GBM thickening in diabetic rats was not influenced by aminoguanidine treatment. Others have recently shown that aminoguanidine ameliorates experimental diabetic nephropathy. In long-term diabetic Wistar rats, aminoguanidine attenuated both urinary factors. Week 8: P < 0.05 diabetic + chronic AG versus diabetic + late intervention; P < 0.05 diabetic + late intervention versus diabetic + early intervention, P < 0.01 diabetic versus control, diabetic + late intervention.
Week 16: P < 0.01 diabetic vs. control, P < 0.05 diabetic + late intervention vs. control; P < 0.01 diabetic vs. diabetic + early intervention.
Week 24: P < 0.01 all diabetic groups vs. control, P < 0.01 diabetic + chronic AG vs. diabetic. Week 32: P < 0.01 diabetic vs. control, diabetic + early intervention vs. control, diabetic + late intervention vs. control, P < 0.01 diabetic + chronic AG vs. diabetic, P < 0.05 diabetic + chronic AG vs. diabetic + early intervention, diabetic + chronic AG vs. diabetic + late intervention.
albumin and high molecular weight protein excretion [26] . In rats with diabetes and genetic hypertension, aminoguanidine retarded the development of albuminuria over a 16 weeks study period [27] . We have previously shown that AG therapy does not significantly influence albuminuria or tissue fluorescence in control rats after 16 weeks of therapy [15] . In the present study, in another group of control rats treated with AG for 32 weeks, a similar lack of effect of AG on albuminuria or on any renal strucural parameter was noted. Other groups have also shown no effect of AG on albuminuria [26] or on kidney related fluorescence [8] in non-diabetic rats. These findings are consistent with AG having a specific role in states of chronic hyperglycemia. One cannot exclude that AG could exert its beneficial effects via other mechanisms including reduction in blood pressure or preventing hyperfiltration. However, in the present study, AG did not influence blood pressure or GFR (data not shown). It should be appreciated that the model of STZ diabetes in the SpragueDawley rat is not associated with renal impairment [28] . Therefore, one cannot predict from these studies if agents such as AG could prevent the decline in renal function in humans. Aminoguanidine has also been shown to favorably influence retinopathy [29] and neuropathy [30] in experimental diabetes. A recent study by Huijberts et al has reported that aminoguanidine Results are means SE. "P < 0.01 vs. Diabetic can reduce regional albumin clearances across various tissue beds although the kidney was not specifically studied [31] . No effect on urinary albumin excretion was observed in that study which was only eight weeks in duration.
To explore the specificity of the changes in tissue fluorescence a recently developed radioimmunoassay was used to measure advanced glycation end products. This assay confirmed that diabetes is associated with an increase in AGEs in both glomeruli and renal tubules and that these changes could be prevented by aminoguanidine therapy (Fig. 3) . Using immunohistochemical techniques we have also demonstrated the presence of AGEs in both glomeruli and renal tubules [32] . RAGE (receptor to advanced glycation end products), a 30 kDa protein postulated to be involved in AGE actions, has been reported to be present in the kidney [33] . In studies which included use of an antibody to human RAGE, advanced glycated products and RAGE appeared to co-localize in glomeruli and distal tubules [32] .
Even though the effect of aminoguanidine in retarding renal injury has been confirmed in the present study, its mechanism of action remains unclear. The ability of aminoguanidine to reduce tissue fluorescence suggests that its major action is via prevention of AGE product accumulation. However, fluorescence per se cannot be considered specific for AGEs since other compounds such as oxidation products may fluoresce [34] . This is further complicated by a well described interaction between glycation and oxidation resulting in glycoxidation products, some of which fluoresce [35] . A recent study by Dyer et al has shown a strong correlation between glycoxidation products such as carboxymethyllysine and pentosidine and tissue fluorescence in both control and diabetic patients [2] . Our group has compared treatment of diabetic rats with either antioxidants or aldose reductase inhibitors with aminoguanidine treatment [36] . These agents failed to reproduce the renal effects of aminoguanidine over 32 weeks. This suggests that the in vivo effects of aminoguanidine are mediated predominantly via inhibition of advanced glycation rather than by inhibition of alternative pathways such as the polyoi pathway or oxidation alone. In the present study, the ability of AG to reduce renal AGEs, as assessed by radioimmunoassay, provides further evidence that AG acts predominantly as an inhibitor of advanced glycation.
The major structural parameter to be ameliorated by aminoguanidine was mesangial expansion which has been postulated to be a central mechanism in the progression of diabetic renal injury [37] . Recently, Anderson et al have shown that in vitro glycation of extracellular matrix could influence mesangial cell behavior [38] . However, this group did not differentiate between early and advanced glycation. This is of particular significance because of recent studies suggesting that Amadori products may participate in the genesis of renal injury in diabetes [39, 40] . In the 0 8 16 
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present study, there was a tendency for mesangial exxpansion to already be apparent after only a short period of diabetes. This is consistent with previous studies which have observed that increases in mesangial volume are already detectable after 8 or 24 weeks of diabetes [41, 421 . Furthermore, islet transplantation has been shown to reverse mesangial expansion in diabetic rats within eight weeks [43] , consistent with the ability of glucose-dependent mechanisms to rapidly influence this glomerular ultrastructural parameter [43] .
The link between AGEs and mesangial expansion is further strengthened by several reports indicating that receptors for advanced glycation products are present in mesangial cells [33, 44] . It appears likely that mesangial expansion in diabetes not only involves increased synthesis of matrix components but also a decrease in matrix degradation [45] . Aminoguanidine has been shown to normalize the defect in matrix degradation that occurs when matrix is incubated in a high glucose medium [45] . Therefore it is possible that the effects of aminoguanidine in preventing mesangial expansion, may be in part due to the capacity of this drug to normalize mesangial matrix degradative processes.
A recent study has shown that AGE-modified mouse serum albumin injected intraperitoneally for four weeks was associated with an increase in the messenger RNA for various extracellular matrix components and growth factors including alpha-i IV collagen, laminin Bi and transforming growth factor -1 [461. In addition, aminoguanidine was able to inhibit these increases in growth factor and matrix component gene expression. These findings would be consistent with aminoguanidine preventing mesangial expansion by inhibiting AGE-dependent mechanisms which regulate growth factor and extracellular matrix synthesis. More recently, this group has demonstrated that administration of in vitro prepared AGEs to normal rats for five months leads to advanced pathological changes in renal glomerular structure and function [47] . These rats developed albuminuria and an increase in mesangial matrix. These changes were associated with increased renal and serum AGE levels. Aminoguanidine was able to inhibit the accumulation of renal AGEs as well as preventing albuminuria in this model. However, it is not known how closely the pathology of the renal lesion in response to administration of in vitro generated AGEs reflects diabetic nephropathy in other respects.
Treatment with aminoguanidine for 32 weeks was more effective in preventing renal injury than 16 weeks of treatment, either early or late. These findings are consistent with a recent study that showed that the duration of AG treatment was important in retarding the progression of experimental retinopathy [48] .
There was no difference between early and late intervention with respect to albuminuria or mesangial expansion. This would indicate that aminoguanidine treatment has a role not only in preventing diabetic complications but that this agent could also be considered in the setting of established diabetic renal disease.
Interestingly, our study showed no difference in the effect of aminoguanidine on tissue fluorescence when the drug was given throughout the study, or when it was administered early or late (Fig. 2) . By contrast, the effects of aminoguanidine on albuminuria and renal structure, as described above, were influenced by duration of therapy. Possible explanations for this difference may be that not all AGEs are fluorescent [49] or that the tissue fluorescence observed in this study reflects other processes as well as advanced glycation. Therefore a direct link between tissue fluorescence and renal structural changes in diabetes remains to be determined. The link between tissue levels AGE and albuminuria has been recently studied in diabetic patients by Beisswenger et al [50] . In that study advanced glycation end products, as assessed by collagen-linked fluorescence and pentosidine, measured by a specific HPLC technique, were found to correlate with micro-and macroalbuminuria.
The present results are consistent with the hypothesis that advanced glycation is an important pathogenetic process in the development of diabetic complications, including nephropathy. The demonstration that aminoguanidine therapy has a renoprotective effect and that the effect is related to the duration of therapy, emphasises its potential importance in the clinical situation. Although caution is needed in extrapolating the results of experimental studies to clinical diabetes, the potent effects of aminoguanidine on diabetic microvascular complications observed in experimental studies should be a major impetus to further explore the effects of this drug in humans.
